Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies

NCT00237627 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT00237627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00237627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2001
Completion date
January 31, 2010
Enrollment
107 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, ovarian cancer, unspecified adult solid tumor, protocol specific